SCTX — Scribe Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1853921 ·
Last close
$21.77
Market Cap
—
52W High
$39.60
52W Low
$17.31
ADV30
361,150
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,918,000 | — | -9,395,000 | -6,477,000 | 57,927,000 | 35,586,000 | 222,773,000 |
| Mar 2026 | 2,233,000 | — | -12,427,000 | -17,347,000 | 65,208,000 | 20,381,000 | 223,946,000 |
| Jun 2025 | 4,898,000 | — | -11,627,000 | -9,903,000 | — | — | — |
| Mar 2025 | 17,125,000 | — | -5,557,000 | -3,425,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,176,000
Investing CF
$36,469,000
Financing CF
$-413,000
CapEx
$-508,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-175,054,000
Inventory
—
Receivables
$1,521,000
ST Investments
$29,350,000
EBIT TTM
$-19,663,000
Pretax Income TTM
$-20,859,000
Interest Exp TTM
$1,196,000
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,174,000 | -26,070,000 | -21,808,000 | 78,219,000 | 221,638,000 | -143,419,000 | -45,213,000 |
| Dec 2024 | 27,413,000 | -42,829,000 | -47,786,000 | 127,971,000 | 253,830,000 | -125,859,000 | -45,235,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $226.05B | $418.13 | — |
| GILD | GILEAD SCIENCES, INC. | $188.73B | $152.21 | — |
| MRNA | Moderna, Inc. | $78.76B | $197.28 | — |
| ARGX | ARGENX SE | $60.46B | $972.25 | — |
| RVMD | Revolution Medicines, Inc. | $43.24B | $201.74 | — |
News headlines (Yahoo Finance, 1h cache)
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-22 11:10 · Yahoo
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
2026-09-17 20:09 · Yahoo
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-09-02 20:05 · Yahoo
Scribe Therapeutics to Participate in Upcoming Investor Conferences
2026-09-01 12:00 · Yahoo
Cathie Wood Makes $64 Million Bet on Two Stocks
2026-09-28 19:11 · Yahoo
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-31 13:45 · Yahoo
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
2026-08-18 13:37 · Yahoo
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
2026-07-30 14:26 · Yahoo
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
2026-07-27 20:05 · Yahoo
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
2026-07-24 18:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.